News

Innovative Patents Granted to Catheter Precision, Inc. Expand Portfolio

Innovative Patents Granted to Catheter Precision, Inc. Expand Portfolio

Significant Patent Advancements for Catheter Precision, Inc.

Catheter Precision, Inc. (VTAK - NYSE/American), a leading medical device company specializing in advanced technologies for cardiac electrophysiology, is thrilled to announce an exciting development in its intellectual property portfolio. The United States Patent and Trademark Office has approved two pivotal patents, strengthening the company's innovative capabilities in this crucial sector.

Understanding the New Patents

The first patent focuses on “Methods of Ventricular Arrhythmia Localization Using a 3D Model.” This remarkable innovation further solidifies the VIVO technology portfolio. It will benefit from the collaboration with Kardionav, a joint venture aimed at enhancing cardiac ventilatory therapies by applying advanced methodologies.

Furthermore, the second patent, “Neurostimulation Devices and Methods,” targets enhancements in cardiac ventricular functions, particularly among patients suffering from heart failure. This initiative will be part of Cardionomix, a subsidiary that aims to provide state-of-the-art heart failure therapies through specific nerve stimulation techniques. This patent represents a crucial step in addressing the complexities associated with cardiac health.

CEO Insights on Patent Approvals

David Jenkins, the CEO of Catheter Precision, expressed his enthusiasm regarding the newly acquired patents. He stated, “We are excited that our intellectual property is being recognized with these patent approvals. Each grant is a testament to the value and uniqueness of our technological advancements in the competitive market of medical devices.” This affirming acknowledgment is projected to reinforce the company's determination to innovate continuously and create impactful solutions.

Overview of VIVO Technology

About VIVO™
VIVO (View Into Ventricular Onset) is Catheter Precision's groundbreaking non-invasive 3D imaging system. It empowers healthcare professionals by allowing them to identify the origins of ventricular arrhythmias before procedures, thus streamlining clinical workflows and reducing procedural timelines. Notably, VIVO has obtained marketing clearance from the U.S. FDA and carries the CE Mark, signifying its compliance with international health and safety standards.

About Catheter Precision, Inc.

About Catheter Precision
As a pioneering player in the medical device industry, Catheter Precision is dedicated to introducing innovative solutions aimed at enhancing cardiac arrhythmia treatments. The company’s focus lies in developing cutting-edge technologies for electrophysiology procedures by working closely with medical professionals and continuously refining its product line.

Future Outlook and Growth Potential

The recent patent grants mark just the beginning of a wider vision for Catheter Precision. The company is adamant about expanding its portfolio and pursuing additional applications to cater to complex cardiac conditions. With ongoing research and development, notable expectations for future technologies and treatments are on the horizon.

Frequently Asked Questions

What are the new patents by Catheter Precision?

Catheter Precision has received patents for methods of ventricular arrhythmia localization and neurostimulation devices aimed at improving heart function.

How does VIVO technology enhance procedures?

VIVO technology allows physicians to identify the source of ventricular arrhythmias pre-procedure, which streamlines workflow and reduces procedure time.

Who is the CEO of Catheter Precision?

The current CEO of Catheter Precision is David Jenkins, who emphasizes the importance of continuous innovation.

What does Cardionomix focus on?

Cardionomix, a subsidiary of Catheter Precision, is focused on heart failure therapies using advanced neurostimulation techniques.

What is the goal of Catheter Precision?

The primary goal of Catheter Precision is to develop innovative medical devices that improve the treatment of cardiac arrhythmias through collaboration and technology advancement.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 120

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 79

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 111

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
Shenzhen’s 50-Year Message Carries Real Trade Weight

Updated Category News Views 68

A city once framed as a frontier fishing village is being presented as China’s sharpest recent economic before-and-after picture. At the welcome dinner for the 33rd APEC Economic Leaders’ Meeting in Shenzhen, President Xi Jinping gave guests a compact geographic guide to China’s past: Xi’an for thousands of years, Beijing for 500 years, Shanghai for 100 years, and...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 73

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 94

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
Mimic Bets Virtual Patching Can Calm AI Patch Chaos

Updated Category News Views 100

Three ugly outages in four days can make even hardened technology buyers reconsider the sacred ritual of “patch immediately.” Mimic’s new Virtual Patching offering arrives squarely in that uncomfortable gap: a vulnerability is known, attackers may be moving fast, and the proper vendor update still needs testing before somebody detonates production. The company’s...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 31

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 85

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
SQM Investigation Puts Chile Approval Claims on Trial

Updated Category News Views 71

A Regulatory Promise Meets a Rough Earnings Reaction A 5.52% haircut after disappointing quarterly numbers is the sort of thing that makes shareholders stop pretending every loose management comment is harmless. Sociedad Química y Minera de Chile, NYSE:SQM, is facing an investigation by Levi & Korsinsky into public statements concerning regulatory matters, particularly...

Continue Reading